PLK2 and Parkinson disease: In this study, we used a validated PLK2-inhibitor, compound 37 [21, 23, 24], and the PLK1-3 inhibitor BI2536 [25], to investigate the role of PLK2 in the S129-phosphorylation of α-syn aggregates in PD models induced by pre-formed α-syn fibrils (PFFs).